Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

NCT06836726 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06836726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06836726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2030
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer